Advertisement

JBIC Journal of Biological Inorganic Chemistry

, Volume 14, Issue 7, pp 1139–1149 | Cite as

Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study

  • Angela CasiniEmail author
  • Gerhard Kelter
  • Chiara Gabbiani
  • Maria Agostina Cinellu
  • Giovanni Minghetti
  • Dolores Fregona
  • Heinz-Herbert Fiebig
  • Luigi MessoriEmail author
Original Paper

Abstract

The antiproliferative properties of a group of 13 structurally diverse gold(III) compounds, including six mononuclear gold(III) complexes, five dinuclear oxo-bridged gold(III) complexes, and two organogold(III) compounds, toward several human tumor cell lines were evaluated in vitro using a systematic screening strategy. Initially all compounds were tested against a panel of 12 human tumor cell lines, and the best performers were tested against a larger 36-cell-line panel. Very pronounced antiproliferative properties were highlighted in most cases, with cytotoxic potencies commonly falling in the low micromolar—and even nanomolar—range. Overall, good-to-excellent tumor selectivity was established for at least seven compounds, making them particularly attractive for further pharmacological evaluation. Compare analysis suggested that the observed antiproliferative effects are caused by a variety of molecular mechanisms, in most cases “DNA-independent,” and completely different from those of platinum drugs. Remarkably, some new biomolecular systems such as histone deacetylase, protein kinase C/staurosporine, mammalian target of rapamycin/rapamycin, and cyclin-dependent kinases were proposed for the first time as likely biochemical targets for the gold(III) species investigated. The results conclusively qualify gold(III) compounds as a promising class of cytotoxic agents, of outstanding interest for cancer treatment, while providing initial insight into their modes of action.

Graphical Abstract

A series of gold(III) compounds showed cytotoxic properties and tumor selectivity toward a panel of cancer cell lines. Compare analysis provided insight into their possible mechanisms of action.

Keywords

Anticancer drug Structure–function relationship 

Notes

Acknowledgments

We gratefully acknowledge support from Ente Cassa di Risparmio di Firenze and from the Italian Consortium C.I.R.C.M.S.B. C.G. wishes to thank AIRC for providing her with a Research Fellowship. A.C. thanks the Swiss National Science Foundation for financial support (project number PZ00P2_121933).

Supplementary material

775_2009_558_MOESM1_ESM.pdf (1.9 mb)
Supplementary material (PDF 1987 kb)

References

  1. 1.
    Barnes KR, Lippard SJ (2004) Met Ions Biol Syst 42:143–177PubMedGoogle Scholar
  2. 2.
    Reedijk J (2003) Proc Natl Acad Sci USA 100:3611–3616PubMedCrossRefGoogle Scholar
  3. 3.
    Wang D, Lippard SJ (2005) Nat Rev Drug Discov 4:307–320PubMedCrossRefGoogle Scholar
  4. 4.
    Sigel A, Sigel H (2004) Metal ions in biological systems. Marcel Dekker, New YorkGoogle Scholar
  5. 5.
    Sigel A, Sigel H (2005) Metal ions in biological systems. Wiley, New YorkGoogle Scholar
  6. 6.
    Jakupec M, Keppler BK (2004) In: Sigel A, Sigel H (ed) Metal ions in biological systems. Marcel Dekker, New YorkGoogle Scholar
  7. 7.
    Bruijnincx PCA, Sadler PJ (2008) Curr Opin Chem Biol 12:197–206PubMedCrossRefGoogle Scholar
  8. 8.
    Alessio E, Mestroni G, Bergamo A, Sava G (2004) Curr Top Med Chem 4:1525–1535PubMedCrossRefGoogle Scholar
  9. 9.
    Ang WH, Dyson PJ (2006) Eur J Inorg Chem 4003–4018Google Scholar
  10. 10.
    Milacic V, Fregona D, Dou QP (2008) Histol Histopathol 23:101–108PubMedGoogle Scholar
  11. 11.
    Casini A, Hartinger C, Gabbiani C, Mini E, Dyson PJ, Keppler BK, Messori L (2008) J Inorg Biochem 102:564–575PubMedCrossRefGoogle Scholar
  12. 12.
    Parish RV, Howe BP, Wright JP, Mack J, Pritchard RG, Buckley RG, Elsome AM, Fricker SP (1996) Inorg Chem 35:1659–1666PubMedCrossRefGoogle Scholar
  13. 13.
    Parish RV, Mack J, Hargreaves L, Wright JP, Buckley RG, Elsome AM, Fricker SP, Theobald BRC (1996) J Chem Soc Dalton Trans 69–74Google Scholar
  14. 14.
    Giovagnini L, Ronconi L, Aldinucci D, Lorenzon D, Sitran S, Fregona D (2005) J Med Chem 48:1588–1595PubMedCrossRefGoogle Scholar
  15. 15.
    Che CM, Sun RWY, Yu WY, Ko CB, Zhu NY, Sun HZ (2003) Chem Commun 1718–1719Google Scholar
  16. 16.
    Gabbiani C, Casini A, Messori L (2007) Gold Bull 40:73–81Google Scholar
  17. 17.
    Carotti S, Marcon G, Marussich M, Mazzei T, Messori L, Mini E, Orioli P (2000) Chem Biol Interact 125:29–38PubMedCrossRefGoogle Scholar
  18. 18.
    Ronconi L, Marzano C, Zanello P, Corsini M, Miolo G, Macca C, Trevisan A, Fregona D (2006) J Med Chem 49:1648–1657PubMedCrossRefGoogle Scholar
  19. 19.
    Rigobello MP, Messori L, Marcon G, Cinellu MA, Bragadin M, Folda A, Scutari G, Bindoli A (2004) J Inorg Biochem 98:1634–1641CrossRefGoogle Scholar
  20. 20.
    Saggioro D, Rigobello MP, Paloschi L, Folda A, Moggach SA, Parsons S, Ronconi L, Fregona D, Bindoli A (2007) Chem Biol 14:1128–1139PubMedCrossRefGoogle Scholar
  21. 21.
    Rigobello MP, Scutari G, Folda A, Bindoli A (2004) Biochem Pharmacol 67:689–696PubMedCrossRefGoogle Scholar
  22. 22.
    Rackham O, Nichols SJ, Leedman PJ, Berners-Price SJ, Filipovska A (2007) Biochem Pharmacol 74:992–1002PubMedCrossRefGoogle Scholar
  23. 23.
    Omata Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D, Bouillaguet S, Sano H, Lewis JB, Wataha JC (2006) Toxicol In Vitro 20:882–890PubMedCrossRefGoogle Scholar
  24. 24.
    Barnard PJ, Berners-Price SJ (2007) Coord Chem Rev 251:1889–1902CrossRefGoogle Scholar
  25. 25.
    Engman L, McNaughton M, Gajewska M, Kumar S, Birmingham A, Powis G (2006) Anticancer Drugs 17:539–544PubMedCrossRefGoogle Scholar
  26. 26.
    Wang Y, He QY, Sun RW, Che CM, Chiu JF (2005) Cancer Res 65:11553–11564PubMedCrossRefGoogle Scholar
  27. 27.
    Milacic V, Chen D, Ronconi L, Landis-Piwowar KR, Fregona D, Dou QP (2006) Cancer Res 66:10478–10486PubMedCrossRefGoogle Scholar
  28. 28.
    Wang Y, He QY, Che CM, Tsao SW, Sun RW, Chiu JF (2008) Biochem Pharmacol 75:1282–1291PubMedCrossRefGoogle Scholar
  29. 29.
    Ronconi L, Giovagnini L, Marzano C, Bettio F, Graziani R, Pilloni G, Fregona D (2005) Inorg Chem 44:1867–1881PubMedCrossRefGoogle Scholar
  30. 30.
    Messori L, Abbate F, Marcon G, Orioli P, Fontani M, Mini E, Mazzei T, Carotti S, O’Connell T, Zanello P (2000) J Med Chem 43:3541–3548PubMedCrossRefGoogle Scholar
  31. 31.
    Marcon G, Carotti S, Coronnello M, Messori L, Mini E, Orioli P, Mazzei T, Cinellu MA, Minghetti G (2002) J Med Chem 45:1672–1677PubMedCrossRefGoogle Scholar
  32. 32.
    Abbate F, Orioli P, Bruno B, Marcon G, Messori L (2000) Inorg Chim Acta 311Google Scholar
  33. 33.
    Coronnello M, Mini E, Caciagli B, Cinellu MA, Bindoli A, Gabbiani C, Messori L (2005) J Med Chem 48:6761–6765PubMedCrossRefGoogle Scholar
  34. 34.
    Casini A, Cinellu MA, Minghetti G, Gabbiani C, Coronnello M, Mini E, Messori L (2006) J Med Chem 49:5524–5531PubMedCrossRefGoogle Scholar
  35. 35.
    Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) J Natl Cancer Inst 81:1088–1092PubMedCrossRefGoogle Scholar
  36. 36.
    Huang RL, Wallqvist A, Covell DG (2005) Biochem Pharmacol 69:1009–1039PubMedCrossRefGoogle Scholar
  37. 37.
    Boyd MR, Paull KD, Rubinstein LR (1992) In: Valeriote FA, Corbett T, Backer L (eds) Cytotoxic anticancer models and concepts for drug discovery and development. Kluwer, Amsterdam, pp 11–34Google Scholar
  38. 38.
    Roth T, Burger AM, Dengler W, Willmann H, Fiebig HH (1999) In: Fiebig HH, Burger AM (eds) Contrib oncol, pp 145–156Google Scholar
  39. 39.
    Fiebig HH, Dengler WA, Roth T (1999) In: Fiebig HH, Burger AM (eds) Contrib Oncol, pp 29–50Google Scholar
  40. 40.
    Fiebig HH, Berger DP, Dengler WA, Wallbrecher E, Winterhalter BR (1992) In: Fiebig HH, Berger DP (eds) Relevance of tumor models for anticancer drug development. Karger, Basel, pp 321–351Google Scholar
  41. 41.
    Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH (1995) Anti Cancer Drugs 6:522–532PubMedCrossRefGoogle Scholar
  42. 42.
    Fang XL, Shao L, Zhang H, Wang SM (2004) J Chem Inf Comput Sci 44:249–257PubMedGoogle Scholar
  43. 43.
    Elder RC, Watkins JW (1986) Inorg Chem 25:223–226CrossRefGoogle Scholar
  44. 44.
    Kimura E, Kurogi Y, Koike T, Shionoya M, Iitaka Y (1993) 28:33–49Google Scholar
  45. 45.
    Hollis LS, Lippard SJ (1983) J Am Chem Soc 105:4293–4299CrossRefGoogle Scholar
  46. 46.
    Cinellu MA, Minghetti G, Pinna MV, Stoccoro S, Zucca A, Manassero M, Sansoni M (1998) J Chem Soc Dalton Trans 1735–1741Google Scholar
  47. 47.
    Cinellu MA, Minghetti G, Pinna MV, Stoccoro S, Zucca A, Manassero M (2000) J Chem Soc Dalton Trans 8:1261–1265CrossRefGoogle Scholar
  48. 48.
    Cinellu MA, Zucca A, Stoccoro S, Minghetti G, Manassero M, Sansoni M (1996) J Chem Soc Dalton Trans 4217–4225Google Scholar
  49. 49.
    Cinellu MA, Minghetti G, Pinna MV, Stoccoro S, Zucca A, Manassero M (1999) J Chem Soc Dalton Trans 2823–2831Google Scholar
  50. 50.
    Cinellu MA, Minghetti G, Pinna MV, Stoccoro S, Zucca A, Manassero M (2003) Eur J Inorg Chem 2304–2310Google Scholar
  51. 51.
    Ronconi L, Maccato C, Barreca D, Saini R, Zancato M, Fregona D (2005) Polyhedron 24:521–531CrossRefGoogle Scholar
  52. 52.
    Gabbiani C, Casini A, Messori L, Guerri A, Cinellu MA, Mlnghetti G, Corsini M, Rosani C, Zanello P, Arca M (2008) Inorg Chem 47:2368–2379PubMedCrossRefGoogle Scholar
  53. 53.
    Sanna G, Pilo MI, Spano N, Minghetti G, Cinellu MA, Zucca A, Seeber R (2001) J Organomet Chem 622:47–53CrossRefGoogle Scholar
  54. 54.
    Messori L, Marcon G, Cinellu MA, Coronnello M, Mini E, Gabbiani C, Orioli P (2004) Bioorg Med Chem 12:6039–6043PubMedCrossRefGoogle Scholar
  55. 55.
    Koelle U, Laguna A (1999) Inorg Chim Acta 290:44–50CrossRefGoogle Scholar
  56. 56.
    Castillo A, Morse HC, Godfrey VL, Naeem R, Justice MJ (2007) Cancer Res 67:10138–10147PubMedCrossRefGoogle Scholar
  57. 57.
    Horn D (2008) Adv Exp Med Biol 625:81–86PubMedCrossRefGoogle Scholar
  58. 58.
    Hadnagy A, Beaulieu R, Balicki D (2008) Mol Cancer Ther 7:740–748PubMedCrossRefGoogle Scholar
  59. 59.
    Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH (2009) Cancer Treat Rev 35:1–8PubMedCrossRefGoogle Scholar
  60. 60.
    Mackay HJ, Twelves CJ (2007) Nat Rev Cancer 7:554–562PubMedCrossRefGoogle Scholar
  61. 61.
    Guertin DA, Sabatini DM (2005) Trends Mol Med 11:353–361PubMedCrossRefGoogle Scholar
  62. 62.
    Sharma PS, Sharma R, Tyagi R (2008) Curr Cancer Drug Targets 8:53–75PubMedCrossRefGoogle Scholar

Copyright information

© SBIC 2009

Authors and Affiliations

  • Angela Casini
    • 1
    Email author
  • Gerhard Kelter
    • 2
  • Chiara Gabbiani
    • 3
  • Maria Agostina Cinellu
    • 4
  • Giovanni Minghetti
    • 4
  • Dolores Fregona
    • 5
  • Heinz-Herbert Fiebig
    • 2
  • Luigi Messori
    • 3
    Email author
  1. 1.Laboratory of Organometallic and Medicinal Chemistry, Institut des Sciences et Ingénierie ChimiquesEcole Polytechnique Fédérale de Lausanne (EPFL)LausanneSwitzerland
  2. 2.Institute for Experimental OncologyOncotest GmbHFreiburgGermany
  3. 3.Laboratory of Metals in Medicine, Department of ChemistryUniversity of FlorenceSesto FiorentinoItaly
  4. 4.Department of ChemistryUniversity of SassariSassariItaly
  5. 5.Department of Chemical SciencesUniversity of PaduaPaduaItaly

Personalised recommendations